Buformin

Chemistry and animal toxicology

Buformin hydrochloride is a fine, white to slightly yellow, crystalline, odorless powder, with a weakly acidic bitter taste. Its melting point is 174 to 177 °C, it is a strong base, and is freely soluble in water, methanol and ethanol, but insoluble in chloroform and ether. Toxicity: guinea pig LD50 subcutaneous 18 mg/kg; mouse LD50 intraperitoneal 140 mg/kg and 300 mg/kg oral. The log octanol-water partition coefficient (log P) is -1.20E+00; its water solubility is 7.46E+05 mg/L at 25 °C. Vapor pressure is 1.64E-04 mm Hg at 25 °C (EST); Henry's law constant is 8.14E-16 atm-m3/mole at 25 °C (EST). Its Atmospheric -OH rate constant is 1.60E-10 cm3/molecule-sec at 25 °C.

Mechanism of action

Buformin delays absorption of glucose from the gastrointestinal tract, increases insulin sensitivity and glucose uptake into cells, and inhibits synthesis of glucose by the liver. Buformin and the other biguanides are not hypoglycemic, but rather antihyperglycemic agents. They do not produce hypoglycemia; instead, they reduce basal and postprandial hyperglycemia in diabetics. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels.

Pharmacokinetics

After oral administration of 50 mg of buformin to volunteers, almost 90% of the applied quantity was recovered in the urine; the rate constant of elimination was found to be 0.38 per hr. Buformin is a strong base (pKa = 11.3) and not absorbed in the stomach. After intravenous injection of about 1 mg/kg buformin-14-C, the initial serum concentration is 0.2-0.4 μg/mL. Serum level and urinary elimination rate are linearly correlated. In man, after oral administration of 50 mg 14-C-buformin, the maximum serum concentration was 0.26-0.41 μg/mL. The buformin was eliminated with an average half-life of 2 h. About 84% of the dose administered was found excreted unchanged in the urine. Buformin is not metabolized in humans. The bioavailability of oral buformin and other biguanides is 40%-60%. Binding to plasma proteins is absent or very low.

Dosage

The daily dose of buformin is 150–300 mg by mouth. Buformin has also been available in a sustained release preparation, Silubin Retard, which is still sold in Romania.

Side effects and contraindications

The side effects encountered are anorexia, nausea, diarrhea, metallic taste, and weight loss. Its use is contraindicated in diabetic coma, ketoacidosis, severe infection, trauma, other conditions where buformin is unlikely to control the hyperglycemia, renal or hepatic impairment, heart failure, recent myocardial infarct, dehydration, alcoholism, and conditions likely to predispose to lactic acidosis.

Toxicity

In one report, the toxic oral dose was 329 ± 30 mg/day in 24 patients who developed lactic acidosis on buformin. Another group of 24 patients on 258 ± 25 mg/day did not develop lactic acidosis on buformin.

Anticancer properties

Buformin, along with phenformin and metformin, inhibits the growth and development of cancer. The anticancer property of these drugs is due to their ability to disrupt the Warburg effect and revert the cytosolic glycolysis characteristic of cancer cells to normal oxidation of pyruvate by the mitochondria. Metformin reduces liver glucose production in diabetics and disrupts the Warburg effect in cancer by AMPK activation and inhibition of the mTor pathway. Buformin decreased cancer incidence, multiplicity, and burden in chemically induced rat mammary cancer, whereas metformin and phenformin had no statistically significant effect on the carcinogenic process relative to the control group. Buformin also exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells, lung cancer cells and cervical cancer cells.

Antiviral properties

Biguanides were first noted to be active against influenza in the 1940s. Further studies confirmed their antiviral activity in vitro. Buformin, especially, was potently antiviral against vaccinia and influenza. Buformin is a metabolic antiviral that inhibits the mTOR pathway used by influenza and Middle East respiratory syndrome-related coronavirus.

History

Buformin was synthesized as an oral antidiabetic in 1957.

Synthesis

Buformin is obtained by reaction of butylamine and 2-cyanoguanidine.

References

References

1. (1964). "[New Pharmacologic Products. 2. Buformin For Oral Therapy Of Diabetes]". Pharmazeutische Praxis.
2. (1974). "Isolation and identification of drugs in pharmaceuticals, body fluids and post-mortem material". Pharmaceutical Press, Pharmaceutical Society of Great Britain. Dept. of Pharmaceutical Sciences..
3. (December 1981). "Chemistry and hypoglycemic activity of benzimidoylpyrazoles". Journal of Medicinal Chemistry.
4. United States National Library of Medicine ChemLDplus advanced database
5. (2011). "The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs.". Wiley.
6. (February 2013). "Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP". Nature.
7. (March 1968). "The fate of biguanides in man". Annals of the New York Academy of Sciences.
8. (September 1971). "Evaluation of a sustained release form of the oral antidiabetic butylbiguanide (Silubin retard)". European Journal of Clinical Pharmacology.
9. (October 1991). "Pharmacokinetic optimisation of oral hypoglycaemic therapy". Clinical Pharmacokinetics.
10. (1976). "[Concentration of 14C-1-butylbiguanide in plasma of diabetic patients and its elimination after administration of a new Galenical formulation (author's transl)]". Arzneimittel-Forschung.
11. (1978). "[Distribution and excretion of 14c-butylbiguanide in man (author's transl)]". Arzneimittel-Forschung.
12. (1973). "Textbook of pharmacology.". Academic Press.
13. (June 2005). "Antidiabetic drug utilization in hungary". Pharmacy World & Science.
14. (2005). "[Practice of antidiabetic therapy in Hungary]". Acta Pharmaceutica Hungarica.
15. (1990). "Drugs available abroad.". Gale Research Inc.; Derwent Publications, Ltd.
16. (1981). "Buformin concentrations in a case of fatal lactic acidosis". Diabetologia.
17. (May 2004). "A validated HPLC method with ultraviolet detection for the determination of buformin in plasma". Biomedical Chromatography.
18. (September 2020). "Postmortem distribution/redistribution of buformin in body fluids and solid tissues in an autopsy case using liquid chromatography-tandem mass spectrometry with QuEChERS extraction method". Forensic Science International.
19. (January 1977). "[Lactic acidosis in diabetics on biguanides (author's transl)]". Deutsche Medizinische Wochenschrift.
20. (December 1976). "[10 cases of lactic acidosis during biguanide therapy (buformin and phenformin)]". Schweizerische Medizinische Wochenschrift.
21. (September 1978). "[Lactic acidosis--a possible complication in buformin-treated diabetics (author's transl)]". Klinische Wochenschrift.
22. (February 1978). "Lactic acidosis in biguanide-treated diabetics: a review of 330 cases". Diabetologia.
23. (May 2009). "Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation". Cancer Research.
24. (October 2003). "Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention". Experimental Gerontology.
25. (1980). "The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats". Carcinogenesis.
26. (June 1980). "[Inhibition of the blastomogenic effect of 7,12-dimethylbenz(a)anthracene in female rats by buformin, diphenin, a polypeptide pineal extract and L-DOPA]". Biulleten' Eksperimental'noi Biologii I Meditsiny.
27. (December 2005). "Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens". Annals of the New York Academy of Sciences.
28. (May 2009). "Understanding the Warburg effect: the metabolic requirements of cell proliferation". Science.
29. (December 2005). "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin". Science.
30. (June 2015). "Effects of metformin, buformin, and phenformin on the post-initiation stage of chemically induced mammary carcinogenesis in the rat". Cancer Prevention Research.
31. (2016). "Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells". American Journal of Translational Research.
32. (2019). "The Biguanides Metformin and Buformin in Combination with 2-Deoxy-glucose or WZB-117 Inhibit the Viability of Highly Resistant Human Lung Cancer Cells". Stem Cells International.
33. (June 2018). "Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel". Cancer Biology & Therapy.
34. (September 2017). "Metformin: historical overview". Diabetologia.
35. (March 1968). "Antimicrobial activities of biguanides". Annals of the New York Academy of Sciences.
36. (April 1974). "Antiviral activity of selected biguanide derivatives". Pharmacological Research Communications.
37. (March 1970). "[Effect of Silubin-retard (1-butyl-biguanide hydrochloride) on the course of influenza-virus infection in mice]". Polski Tygodnik Lekarski.
38. (November 1973). "[Influenza epidemic in 1971 in diabetics treated with 1-butyl-biguanidine hydrochloride (Silubin retard) and 1-phenylethyl-biguanidine hydrochloride (Phenformin)]". Polski Tygodnik Lekarski.
39. (May 2020). "Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)". World Academy of Sciences Journal.
40. (February 2015). "Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis". Antimicrobial Agents and Chemotherapy.
41. "Salts Of N-Amylbiguanide.".
42. (1959). "Hypoglycemic Agents. III.1—3N1-Alkyl- and Aralkylbiguanides". Journal of the American Chemical Society.